Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia : A Retrospective Cohort Study With Long-term Follow-up
Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retrospectively analyzed the outcomes of 204 patients with sibling donors who received peripheral stem cells and underwent allo-HSCT of chronic phase I (CP1) in the pre- and post-TKI era at Shariati Hospital in Tehran, Iran, from 1998 to 2017 and followed up till the end of 2021. The median follow-up time for all patients was 8.7 (SD = 0.54) years. Fifteen-year overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free relapse-free survival (GRFS), relapse, and non-relapse mortality (NRM) incidence were 65.70%, 57.83%, 17.56%, 13.17%, and 28.98%, respectively. Using multivariable analyses, the only risk factor increasing the hazard of death was the time between diagnosis to allo-HSCT greater than 1 year compared to this time less than 1 year by 74% [hazard ratio (HR) = 1.74, P = 0.039]. Also, age is a significant risk factor for DFS (HR = 1.03, P = 0.031). Our findings suggested that allo-HSCT is still an important treatment option for CP1 patients, especially those resistant to TKI treatment. TKI consumption can have a desirable effect on NRM after allo-HSCT for CP1 CML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Cell transplantation - 32(2023) vom: 01. Jan., Seite 9636897231163212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tavakoli, Sahar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2023 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/09636897231163212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355180316 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355180316 | ||
| 003 | DE-627 | ||
| 005 | 20231227131206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/09636897231163212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM355180316 | ||
| 035 | |a (NLM)37013251 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tavakoli, Sahar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia |b A Retrospective Cohort Study With Long-term Follow-up |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retrospectively analyzed the outcomes of 204 patients with sibling donors who received peripheral stem cells and underwent allo-HSCT of chronic phase I (CP1) in the pre- and post-TKI era at Shariati Hospital in Tehran, Iran, from 1998 to 2017 and followed up till the end of 2021. The median follow-up time for all patients was 8.7 (SD = 0.54) years. Fifteen-year overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free relapse-free survival (GRFS), relapse, and non-relapse mortality (NRM) incidence were 65.70%, 57.83%, 17.56%, 13.17%, and 28.98%, respectively. Using multivariable analyses, the only risk factor increasing the hazard of death was the time between diagnosis to allo-HSCT greater than 1 year compared to this time less than 1 year by 74% [hazard ratio (HR) = 1.74, P = 0.039]. Also, age is a significant risk factor for DFS (HR = 1.03, P = 0.031). Our findings suggested that allo-HSCT is still an important treatment option for CP1 patients, especially those resistant to TKI treatment. TKI consumption can have a desirable effect on NRM after allo-HSCT for CP1 CML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a chronic phase | |
| 650 | 4 | |a graft versus host disease | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 650 | 7 | |a Tyrosine Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Khalaj, Fattaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Kasaeian, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavi, Seyed Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavian, Amir-Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Rad, Soroush |e verfasserin |4 aut | |
| 700 | 1 | |a Rostami, Shahrbano |e verfasserin |4 aut | |
| 700 | 1 | |a Barkhordar, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Biglari, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Mardani-Fard, Heydar Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Alemi, Hediyeh |e verfasserin |4 aut | |
| 700 | 1 | |a Khavandgar, Naghmeh |e verfasserin |4 aut | |
| 700 | 1 | |a Kamranzadeh Fumani, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Janbabai, Ghasem |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavi, Seied Asadollah |e verfasserin |4 aut | |
| 700 | 1 | |a Ghavamzadeh, Ardeshir |e verfasserin |4 aut | |
| 700 | 1 | |a Vaezi, Mohammad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell transplantation |d 1992 |g 32(2023) vom: 01. Jan., Seite 9636897231163212 |w (DE-627)NLM012659932 |x 1555-3892 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g day:01 |g month:01 |g pages:9636897231163212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/09636897231163212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |b 01 |c 01 |h 9636897231163212 | ||